PRIMARY SCLEROSING CHOLANGITIS (PSC)

Clinical trials for PRIMARY SCLEROSING CHOLANGITIS (PSC) explained in plain language.

Never miss a new study

Get alerted when new PRIMARY SCLEROSING CHOLANGITIS (PSC) trials appear

Sign up with your email to follow new studies for PRIMARY SCLEROSING CHOLANGITIS (PSC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1 Not yet recruiting 2 Completed 1

New drug shows promise for slowing rare liver disease

Disease control Completed

This study tested whether a new oral drug called HTD1801 could help control primary sclerosing cholangitis (PSC), a rare disease that scars the bile ducts in the liver. For 18 weeks, 59 adult patients took either one of two doses of HTD1801 or a placebo pill. The main goal was to…

Matched conditions: PRIMARY SCLEROSING CHOLANGITIS (PSC)

Phase: PHASE2 • Sponsor: HighTide Biopharma Pty Ltd • Aim: Disease control

Last updated Apr 02, 2026 05:26 UTC

PRIMARY SCLEROSING CHOLANGITIS (PSC)

Get alerted when new PRIMARY SCLEROSING CHOLANGITIS (PSC) trials appear

New drug shows promise for slowing rare liver disease